CMV prophylaxis - To do or not to do, that is the question

Nephrology Dialysis Transplantation

Volumn 21, Issue 7, 2006, Pages 1757-1761

  Tan, Ban Hock ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Cytomegalovirus; Ganciclovir prophylaxis; Kidney transplantation; Pre emptive therapy

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PLACEBO; RAPAMYCIN; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANTIBIOTIC RESISTANCE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COLITIS; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG LAVAGE; NOTE; PASSIVE IMMUNIZATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK REDUCTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BONE MARROW CELLS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION;

EID: 33745604257     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl151     Document Type: Note

References (42)

1. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant recipients. Drugs 2004; 64: 2763 2792
2. Tobin JOH. Cytomegalovirus infection. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine, 2nd edn. Oxford University Press, Oxford: 1987, 5.76-5.80
3. Rubin RH. Infections in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host, 4th edn. Kluwer Academic/Plenum, New York: 2002, 573-680
4. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704-708
5. Snydman DR. Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis. Clin Infect Dis 2005; 40: 709-712
6. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. New Engl J Med 1987; 317: 1049-1054
7. Saliba F, Gugenheim J, Samuel D et al. Incidence of cytomegalovirus infection and effects of cytomegalovirus immune globulin prophylaxis after orthotopic liver transplantation. Transplant Proc 1987; 19: 4081-4082
8. Balfour HH,Jr, Chace BA, Stapleton JT et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New Engl J Med 1989; 320: 1381-1387
9. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for the prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New Engl J Med 1988; 318: 70-75
10. Martin M, Manex R, Linden P et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for the prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58: 779-785
11. Badley AD, Seaberg EC, Porayko MK et al. Prophylaxis of cytomegalovirus infection after liver transplantation. Transplantation 1997; 64: 66-73
12. Gane E, Saliba F, Valdecasas GJC et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729-1733
13. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New Engl J Med 1999; 340: 1462-1470
14. Kuypers DRJ, Vanrenterghem YFC. Prophylaxis of cytomegalovirus infection in renal transplantation: New data for an old problem. Nephrol Dial Transplant 1999; 14: 2304-2308
15. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620
16. Gabardi S, Magee CC, Baroletti SA et al. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323-1330
17. Ciancio G, Burke GW, Mattiazzi A et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 2004; 18: 402-406
18. Gruber SA, Garnick J, Morawski K et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 19: 273-278
19. Crumpacker CS. Ganciclovir. New Engl J Med 1996; 335: 721-729
20. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New Engl J Med 1991; 324: 1005-1011
21. Rubin RH. Preemptive therapy in immunocompromised hosts. New Engl J Med 1991; 324: 1057-1059
22. Hibberd PL, Tolkoff-Rubin NE, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995; 123: 18-26
23. The TH, van der Bij W, van den Berg AP et al. Cytomegalovirus antigenemia. Rev Infect Dis 1990; 12 [Suppl 7]: S733-S744
24. Mazzulli T, Rubin RH, Ferraro MJ et al. Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol 1993; 31: 2824-2827
25. Tanabe K, Tokumoto T, Ishikawa N et al. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997; 64: 1721-1725
26. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993; 56: 330-334
27. Gotti E, Suter F, Baruzzo S et al. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clin Tansplant 1996; 10: 550-555
28. Kusne S, Grossi P, Irish W et al. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999; 68: 1125-1131
29. Singh N, Paterson DL, Gayowski T et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Transplantation 2000; 70: 717-722
30. Sagedal S, Nordal KP, Hartman A et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: A randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899-1908
31. Shibolet O, Ilan Y, Kalish Y et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003; 16: 861-865
32. Limaye AP, Corey L, Koelle DM et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649
33. Boivin G, Goyette N, Gilbert C et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615-1618
34. Paya CV, Wilson JA, Espy MJ et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant recipients: A randomized, placebo-controlled trial. J Infect Dis 2002; 185: 854-860
35. Emery VC, Hassan-Walker AF, Burroughs AK et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185: 1723-1728
36. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97: 8039-8044
37. Singh N, Yu VL, Mieles L et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375-381
38. Singh N. Delayed occurrence of cytomegalovirus disease in organ transplant recipients receiving antiviral prophylaxis: Are we winning the battle only to lose the war? Eur J Clin Microbiol Infect Dis 2002; 21: 643-646
39. Kalil AC, Levitsky J, Lyden E et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880
40. Reusser P, Riddell SR, Meyers JD et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373
41. Li CR, Greenberg PD, Gilbert MJ et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979
42. Singhal S, Khan OA, Bramble RA et al. Cytomegalovirus disease following liver transplantation: An analysis of prophylaxis strategies. J Infect 2003; 47: 104-109